My Treatment Approach: My Treatment Approach: Navigating Genetic Testing and RET-Targeted Treatments in NSCLC - Episode 7

Patient and Therapy Considerations Guiding Initiation of Treatment in RET-Positive NSCLC

,

Panelists discuss their initial impressions of a patient case with RET fusion–positive non–small cell lung cancer (NSCLC), treatment goals for newly diagnosed patients, and the key patient and disease characteristics considered when selecting a first-line treatment regimen.

EP. 1: Patient Case: 67 Year-Old Male With Stage IIIB+ NSCLC Awaiting for Mutation Testing
EP. 2: Next Steps to Stage IIIB NSCLC Patient Case Awaiting Molecular Testing and Usability of Liquid Biopsy
EP. 3: Testing Methodologies and Standards in Metastatic NSCLC
EP. 4: Practical Considerations in Metastatic NSCLC: Access and Timing of Testing
EP. 5: Clinical-Decision Making: When to Treat Advanced NSCLC Without Mutational Results
EP. 6: Initial Approach to Management of RET-Positive NSCLC
Now Viewing
EP. 7: Patient and Therapy Considerations Guiding Initiation of Treatment in RET-Positive NSCLC
EP. 8: Considerations for First-Line Targeted Therapies in Metastatic RET-Positive NSCLC
EP. 9: Role of Immunotherapy and Chemotherapy in RET-Positive NSCLC
EP. 10: Managing RET Inhibitor Treatment-Related Adverse Events
  1. Dr Sands to Dr Wakelee: What are your initial impressions of this case? How might you have treated this patient in your practice?
  2. Dr Wakelee to Dr Sands: What are your treatment goals for patients newly diagnosed with RET fusion–positive NSCLC?
  3. Dr Sands: Describe which patient and disease characteristics you consider when selecting a first-line treatment regimen.

Related Content:

My Treatment Approach: My Treatment Approach: Navigating Genetic Testing and RET-Targeted Treatments in NSCLC Video SeriesInsights
Implications of ESMO Guidelines for IGHV-Mutated vs Unmutated CLL
Managing RET Inhibitor Treatment-Related Adverse Events
Role of Immunotherapy and Chemotherapy in RET-Positive NSCLC